Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-7819
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China ; volume:20 ; number:1 ; day:29 ; month:9 ; year:2022 ; pages:1-11 ; date:12.2022
World journal of surgical oncology ; 20, Heft 1 (29.9.2022), 1-11, 12.2022
- Creator
-
Guan, Dandan
Jie, Qiu
Wu, Yihao
Xu, Yuhao
Hong, Weimin
Meng, Xuli
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12957-022-02787-9
- URN
-
urn:nbn:de:101:1-2022121709005015670297
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Guan, Dandan
- Jie, Qiu
- Wu, Yihao
- Xu, Yuhao
- Hong, Weimin
- Meng, Xuli
- SpringerLink (Online service)
Other Objects (12)
Rat Models of Hormone Receptor-Positive Breast Cancer
Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
The impact of CBP expression in estrogen receptor-positive breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Role of BRD4 and histone acetylation in estrogen receptor-positive breast cancers
Rat Models of Hormone Receptor-Positive Breast Cancer
Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
The impact of CBP expression in estrogen receptor-positive breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Role of BRD4 and histone acetylation in estrogen receptor-positive breast cancers
Rat Models of Hormone Receptor-Positive Breast Cancer
Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
The impact of CBP expression in estrogen receptor-positive breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy